Renal Transplant Clinical Trial
Official title:
Cognitive Outcomes and Quality of Life in Stable Renal Transplant Patients Switched fromTwice-Daily Tacrolimus to Envarsus XR™
The purpose of this study is to assess cognitive outcome and quality of life in stable renal transplant patients treated with twice daily tacrolimus at baseline and after switching to Envarsus XL. The study is designed to see if switching patients from Tacrolimus to Envarsus treatment improves cognitive function.
Patients with chronic kidney disease most commonly show cognitive impairments involving attention, memory, executive functions, and mental processing speed. Although data have demonstrated improvements in cognition following kidney transplant and the reversibility of the memory problems evidenced in dialysis, neurotoxicity in transplant patients occurs in >40-50% of the patients treated with tacrolimus. Attention and working memory impairment have been observed in patients treated with sirolimus or tacrolimus, while cyclosporine-treated patients demonstrated performance similar to that of healthy volunteer controls, which may indicate that the cognitive deficit found was partly related to treatment. ENVARSUS XR is a new FDA-approved formulation of tacrolimus. A hallmark difference between ENVARSUS XR and other forms of once- and twice-daily tacrolimus products is the unique, proprietary MeltDose® drug delivery technology (Veloxis Pharmaceuticals, Hørsholm, Denmark) which reduces tacrolimus' particle size to a molecular level. The decreased surface area of the drug particles results in complete absorption and increased bioavailability in a once-daily dosing formulation. In stable kidney transplant patients, ENVARSUS XR pharmacokinetics are characterized by a steadier and more consistent concentration time profile over 24 hours, reduced peak and peak-to-trough fluctuations and similar exposure while benefiting from ~ 20% less total daily dose than twice daily tacrolimus. This open-label, prospective phase clinical trial is designed to evaluate whether switching patients from TAC-IR to ENVARSUS XR treatment improves cognitive function. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01220050 -
Paricalcitol in Reducing Parathyroid Hormone Levels and Ameliorating Markers of Bone Remodelling in Renal Transplant Recipients With Secondary Hyperparathyroidism
|
Phase 2 | |
| Completed |
NCT00820469 -
Study of the Influence of Plasma Exchange on the Pharmacokinetics of Rituximab
|
Phase 4 | |
| Completed |
NCT00239005 -
Enteric-Coated Mycophenolate Sodium on Quality of Life in Patients With Gastrointestinal Symptoms Related to Mycophenolate Mofetil Therapy After Kidney Transplantation
|
Phase 4 | |
| Completed |
NCT00270153 -
The Use of ACE Inhibitors in the Early Renal Post-transplant Period
|
Phase 1 | |
| Completed |
NCT02711826 -
Treg Therapy in Subclinical Inflammation in Kidney Transplantation
|
Phase 1/Phase 2 | |
| Completed |
NCT03837522 -
Trial to Define the Benefits and Harms of Deceased Donor Kidney Procurement Biopsies
|
N/A | |
| Not yet recruiting |
NCT06025240 -
Expanding the Scope of Post-transplant HLA-specific Antibody Detection and Monitoring in Renal Transplant Recipients
|
||
| Completed |
NCT01256294 -
Pharmacokinetics of Generic to Brand Tacrolimus in Stable Renal Transplant Patients
|
Phase 4 | |
| Suspended |
NCT01059292 -
TIPE2 Associated With Kidney Transplant
|
N/A | |
| Completed |
NCT00547040 -
Arterial Stiffness and Calcifications in Incident Renal Transplant Recipients
|
||
| Suspended |
NCT03043339 -
Characterization Of the Intestinal Microbiome Evolution After Kidney Transplant Donation or Receipt
|
||
| Completed |
NCT02581644 -
Assessment of Effectiveness of Belatacept Patient Alert Card in Patients Following Renal Transplantation in a Sample of EU Countries
|
N/A | |
| Completed |
NCT01728012 -
Long-term Cardiovascular Risk Following Successful Renal Transplantation
|
N/A | |
| Terminated |
NCT01011114 -
Using Cinacalcet to Treat the Hypophosphatemia of Early Kidney Transplant
|
N/A | |
| Completed |
NCT02117596 -
Calcineurin Inhibitor Based Immunosuppression Withdrawal
|
N/A | |
| Completed |
NCT00555373 -
Pediatric Kidney Transplant Study of Sirolimus, Mycophenolate Mofetil, and Corticosteroids vs Calcineurin Inhibitor Based Immunosuppression
|
N/A | |
| Recruiting |
NCT05156086 -
Safety and Effectiveness of COVID-19 Vaccine in Kidney Transplant Recipients
|
||
| Completed |
NCT01334333 -
Comparison of Medication Adherence Between Once and Twice Daily Tacrolimus in Stable Renal Transplant Recipients
|
Phase 4 | |
| Recruiting |
NCT03107858 -
The Effect of Norepinephrine Versus Dopamine in Renal Transplant Recipients on Postoperative Graft Function
|
Phase 2/Phase 3 | |
| Completed |
NCT00352547 -
Influence of Genes on Sirolimus Metabolism in Patients With Kidney Transplantation
|
N/A |